Abstract
Allogeneic hematopoietic stem cell transplantation (aHSCT) is used as a curative treatment in severe hematological and immunological disorders. Despite clear improvement of the aHSCT outcome, substantial proportion of patients still suffers from severe complications, including graft-versus-host disease (GvHD). The aim of this study was, therefore, to identify inflammation-associated molecules deregulated in the early serum samples of the patients after aHSCT and nominate markers associated with particular aHSCT parameters/complications. Serum concentrations of 92 inflammation-associated proteins were measured in samples obtained from 80 aHSCT patients 14 days after transplantation and from 23 healthy control subjects by a novel sensitive proximity extension assay technology using Proseek Multiplex Inflammation I kit. Serum profiles of inflammatory proteins in patients after aHSCT were substantially different from those observed in control subjects and related to underlying disease status before transplantation. Particularly, the difference between aHSCT patients and controls reached significance level for 57 analytes (40 upregulated, 17 downregulated in aHSCT patients). The concentration of several markers was associated with the level of donor/recipient HLA match (TGF-α: p corr = 0.025, HGF: p corr = 0.036) and with complete donor chimerism at day +30 after allografting (DNER: p corr = 0.042). None of the markers was significantly associated with acute and chronic GvHD after correction. More than half of investigated proteins significantly differed between the samples from aHSCT patients and healthy control subjects as a consequence of the “cytokine storm” after aHSCT. Comparisons of patient’s subgroups based on specific biological/clinical parameters revealed much less evident differences; nevertheless, we nominated several markers associated with the level of donor/recipient HLA match and post-transplant chimerism.
References
Ambruzova Z, Mrazek F, Raida L et al (2009) Possible impact of MAdCAM1 gene single nucleotide polymorphisms to the outcome of allogeneic haematopoietic stem cell transplantation. Hum Immunol 70:457–460
Assarsson E, Lundberg M, Holmquist G et al (2014) Homogenous 96-plex PEA immunoassay exhibiting high sensitivity, specificity, and excellent scalability. PLoS One 9:e95192
Benjamini Y, Hochberg Y (1995) Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc Ser B57:289–300
Cahn JY, Klein JP, Lee SJ et al (2005) Prospective evaluation of 2 acute graft-versus-host (GVHD) grading systems: a joint Société Française de Greffe de Moëlle et Thérapie Cellulaire (SFGM-TC), Dana Farber Cancer Institute (DFCI), and International Bone Marrow Transplant Registry (IBMTR) prospective study. Blood 106:1495–1500
Chien JW, Zhang XC, Fan W et al (2012) Evaluation of published single nucleotide polymorphisms associated with acute GVHD. Blood 119:5311–5319
Choi SW, Reddy P (2014) Current and emerging strategies for the prevention of graft-versus-host disease. Nat Rev Clin Oncol 11:536–547
Cooley S, Weisdorf DJ, Guethlein LA et al (2010) Donor selection for natural killer cell receptor genes leads to superior survival after unrelated transplantation for acute myelogenous leukemia. Blood 116:2411–2419
Ferrara JL, Levine JE, Reddy P et al (2009) Graft-versus-host disease. Lancet 373:1550–1561
Fiema B, Harris AC, Gomez A et al (2012) High throughput sequential ELISA for validation of biomarkers of acute graft-versus-host disease. J Vis Exp 68:pii 4247
Frampton JP, White JB, Simon AB et al (2014) Aqueous two-phase system patterning of detection antibody solutions for cross-reaction-free multiplex ELISA. Sci Rep 4:4878
Gao L, Yuan K, Ding W et al (2016) Notch signaling: a potential therapeutic target for hematologic malignancies. Crit Rev Eukaryot Gene Expr 26:239–246
Gratwohl A, Baldomero H, Passweg J (2013) Hematopoietic stem cell transplantation activity in Europe. Curr Opin Hematol 20:485–493
Greene M, Lai Y, Pajcini K et al (2016) Delta/Notch-like EGF-related receptor (DNER) is not a Notch ligand. PLoS One 11:e0161157
Hill GR, Crawford JM, Cooke KR et al (1997) Total body irradiation and acute graft-versus-host disease: the role of gastrointestinal damage and inflammatory cytokines. Blood 90:3204–3213
Holtan SG, Verneris MR, Schultz KR et al (2015) Circulating angiogenic factors associated with response and survival in patients with acute graft-versus-host disease: results from Blood and Marrow Transplant Clinical Trials Network 0302 and 0802. Biol Blood Marrow Transplant 21:1029–1036
Hori T, Naishiro Y, Sohma H et al (2008) CCL8 is a potential molecular candidate for the diagnosis of graft-versus-host disease. Blood 111:4403–4412
Levine JE, Braun TM, Harris AC et al (2015) A prognostic score for acute graft-versus-host disease based on biomarkers: a multicenter study. Lancet Haematol 2:e21–e29
Lundberg M, Eriksson A, Tran B et al (2011) Homogeneous antibody-based proximity extension assays provide sensitive and specific detection of low-abundant proteins in human blood. Nucleic Acids Res 39:e102
MacMillan ML, Davies SM, Nelson GO et al (2008) Twenty years of unrelated donor bone marrow transplantation for pediatric acute leukemia facilitated by the National Marrow Donor Program. Biol Blood Marrow Transplant 14(9 Suppl):16–22
Magenau JM, Qin X, Tawara I et al (2010) Frequency of CD4(+)CD25(hi)FOXP3(+) regulatory T cells has diagnostic and prognostic value as a biomarker for acute graft-versus-host-disease. Biol Blood Marrow Transplant 16:907–914
Paczesny S, Krijanovski OI, Braun TM et al (2009) A biomarker panel for acute graft-versus-host disease. Blood 113:273–278
Paczesny S, Braun TM, Levine JE et al (2010) Elafin is a biomarker of graft-versus-host disease of the skin. Sci Transl Med 2:13ra2
Paczesny S, Raiker N, Brooks S et al (2013) Graft-versus-host disease biomarkers: omics and personalized medicine. Int J Hematol 98:275–292
Petersdorf EW (2008) Optimal HLA matching in hematopoietic cell transplantation. Curr Opin Immunol 20:588–593
Politikos I, Kim HT, Nikiforow S et al (2015) IL-7 and SCF levels inversely correlate with T cell reconstitution and clinical outcomes after cord blood transplantation in adults. PLoS One 10:e0132564
Przepiorka D, Weisdorf D, Martin P et al (1995) 1994 consensus conference on acute GVHD grading. Bone Marrow Transplant 15:825–828
Reikvam H, Mosevoll KA, Melve GK et al (2012) The pretransplantation serum cytokine profile in allogeneic stem cell recipients differs from healthy individuals, and various profiles are associated with different risks of posttransplantation complications. Biol Blood Marrow Transplant 18:190–199
Shaw BE, Lee F, Krishnamurthy S et al (2015) Caspase-8 polymorphisms result in reduced Alemtuzumab-induced T-cell apoptosis and worse survival after transplantation. Bone Marrow Transplant 50:237–243
Sullivan KM, Agura E, Anasetti C et al (1991) Chronic graft-versus-host disease and other late complications of bone marrow transplantation. Semin Hematol 28:250–259
Toubai T, Tanaka J, Paczesny S et al (2012) Role of cytokines in the pathophysiology of acute graft-versus-host disease (GVHD): are serum/plasma cytokines potential biomarkers for diagnosis of acute GVHD following allogeneic hematopoietic cell transplantation (allo-HCT)? Curr Stem Cell Res Ther 7:229–239
Xun CQ, Thompson JS, Jennings CD et al (1994) Effect of total body irradiation, busulfan-cyclophosphamide, or cyclophosphamide conditioning on inflammatory cytokine release and development of acute and chronic graft-versus-host disease in H-2-incompatible transplanted SCID mice. Blood 83:2360–2367
Acknowledgements
Supported by the Ministry of Health of the Czech Republic projects IGA MH CZ NT12454-5 and MH CZ-DRO (FNOl, 00098892), and by Palacky University Olomouc project IGA_LF_2016_011.
Author information
Authors and Affiliations
Corresponding author
Electronic supplementary material
Below is the link to the electronic supplementary material.
About this article
Cite this article
Mrazek, F., Schneiderova, P., Kriegova, E. et al. Profile of Inflammation-Associated Proteins in Early Post-Transplant Samples of Patients After Allogeneic Hematopoietic Stem Cell Transplantation: a Preliminary Study. Arch. Immunol. Ther. Exp. 64 (Suppl 1), 55–61 (2016). https://doi.org/10.1007/s00005-016-0446-2
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00005-016-0446-2